The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted RLTs.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

The health secretary addressed NHS employees a day after the £29bn NHS funding was announced. A £29bn investment into the ...

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer ...

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.

Geopolitical disturbances across the supply chain are further complicating the complex pharma customs process.